ABCL
AbCellera Biologics·NASDAQ
--
--(--)
--
--(--)
5.41 / 10
Netural
Sentiment shows a solid 7.52/10 fund‑flow rating, with small and medium investors netting inflows despite overall negative trend. Analyst coverage is thin, only one neutral rating, and market expectations are pessimistic amid an 8.15% price decline. Caution advised.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-07
InstitutionLeerink Partners
Times predicted2
Historical Win Rate50.0%
Is money flowing into or out of ABCL?
- ABCL holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.41/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
